Cowen Doubles Down On Royalties
This article was originally published in Start Up
Cowen Healthcare Royalty Partners and its peers are flush with cash and feeling a little adventurous. It might be good news for biotechs and their investors.
You may also be interested in...
The state of venture capital investing in medical devices and biopharmaceuticals can be examined from different angles and perspectives, but each presents the same troubling image: the two sectors are commanding less and less interest from VCs, according to surveys conducted by Start-Up magazine and the National Venture Capital Association.
The diversified investment firm will aim for low-risk investments that bring faster returns to inventors, research institutions and smaller drug developers.
The slowdown and shake-out predicted to occur in the world of venture capital has come. But has it also already gone, too? The industry has certainly retrenched, but there are also signs of new life in the venture sector. For the past two years, we've tracked a few dozen life sciences firms, with an eye on which ones have nearly tapped out their older funds and which have fresh cash to invest in young start-ups. Here's an updated look at the venture fund landscape, showing the firms with full tanks and the ones who are running on empty, based on SEC filings, firm announcements, and our own database and reporting.